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Abstract
Background: For settings with limited laboratory capacity, 2013 World Health Organization (WHO) guidelines recommend
targeted HIV-1 viral load (VL) testing to identify virological failure. We previously developed and validated a clinical
prediction score (CPS) for targeted VL testing, relying on clinical, adherence and laboratory data. While outperforming the
WHO failure criteria, it required substantial calculation and review of all previous laboratory tests. In response, we developed
four simplified, less error-prone and broadly applicable CPS versions that can be done ‘on the spot’.
Methodology/Principal: Findings From May 2010 to June 2011, we validated the original CPS in a non-governmental
hospital in Phnom Penh, Cambodia applying the CPS to adults on first-line treatment .1 year. Virological failure was
defined as a single VL .1000 copies/ml. The four CPSs included CPS1 with ‘current CD4 count’ instead of %-decline-from-
peak CD4; CPS2 with hemoglobin measurements removed; CPS3 having ‘decrease in CD4 count below baseline value’
removed; CPS4 was purely clinical. Score development relied on the Spiegelhalter/Knill-Jones method. Variables
independently associated with virological failure with a likelihood ratio $1.5 or #0.67 were retained. CPS performance
was evaluated based on the area-under-the-ROC-curve (AUROC) and 95% confidence intervals (CI). The CPSs were validated
in an independent dataset. A total of 1490 individuals (56.6% female, median age: 38 years (interquartile range (IQR 33–44));
median baseline CD4 count: 94 cells/mL (IQR 28–205), median time on antiretroviral therapy 3.6 years (IQR 2.1–5.1)), were
included. Forty-five 45 (3.0%) individuals had virological failure. CPS1 yielded an AUROC of 0.69 (95% CI: 0.62–0.75) in
validation, CPS2 an AUROC of 0.68 (95% CI: 0.62–0.74), and CPS3, an AUROC of 0.67 (95% CI: 0.61–0.73). The purely clinical
CPS4 performed poorly (AUROC-0.59; 95% CI: 0.53–0.65).
Conclusions: Simplified CPSs retained acceptable accuracy as long as current CD4 count testing was included. Ease of field
application and field accuracy remains to be defined.
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Introduction
Scaling-up of antiretroviral treatment (ART) is currently
ongoing in low and middle income countries (LMIC), aiming to
initiate 15 million individuals on ART by 2015 [1]. One of the key
challenges for program managers and policy makers in these
countries is how to monitor these individuals for treatment failure,
considering the often limited financial resources at hand [2].
Routine viral load (VL) testing is now recommended by the
World Health Organization (WHO) [3] but, with currently
available technologies, comes at a high cost and is technically
demanding. Thus, it will still take many years before this will be
readily available in routine program settings in many LIMC [4,5].
Instead, for settings with limited VL testing capacity, the 2013
WHO guidelines recommend targeted VL testing [3].
Targeted VL testing, whereby VL testing is done only in
individuals meeting failure criteria, aims to avoid unnecessary and
costly switches to second line treatment for patients with false-
positive ‘screening’ tests [2]. Effective implementation of such a
strategy requires accurate and evidence-based tools to target VL
testing. Whereas most programs have been applying WHO
clinical and immunological failure criteria [6], studies have
consistently demonstrated the low sensitivity and specificity of
these criteria [2,7].
We previously developed a clinical prediction score (CPS) for
virological failure integrating clinical, adherence and laboratory
data [8]. At the same time, we constructed an algorithm
combining the CPS with targeted VL testing (in patients with a
CPS$2). The score performed substantially better than the WHO
failure criteria, and performed well in internal validation
(Cambodia) and external validation (Uganda) [9,10]. Experience
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from Lesotho provided additional support for its use in patients
who were identified based on WHO immunological and clinical
criteria as treatment failure [11]. A few other CPSs have been
developed for the same purpose, but they have either not been
validated, or performed poorly during validation [9,12,13].
Two limitations of the original CPS were identified during the
validation study in Cambodia [10]. Firstly, frequent errors were
made when physicians applied the score, which affected the CPS
performance. Errors in scoring of the individual items were most
commonly seen for items like the percentage decrease from peak
CD4 cell counts or the decline in hemoglobin values since these
items require calculation, and availability and review of all
previous laboratory results. Secondly, the reliance on regular
laboratory monitoring of CD4 count and hemoglobin values limit
implementation of the original CPS in settings where such tests are
not routinely performed. In response to these limitations, we
derived and validated several simplified versions of the original
clinical score, aiming to make the tool less error-prone, easier to
apply and more broadly applicable.
Methods
Study Setting
Sihanouk Hospital Center of HOPE (SHCH) is a non-
governmental hospital in Phnom Penh Cambodia. Since 2003,
the hospital has provided ART at no cost as part of the national
program. Patients were initiated and treated according to WHO
recommendations [6,14]. First line treatment consisted of a
generic combination of stavudine, lamuvidine and nevirapine.
Zidovudine and efavirenz was used in case of contraindications.
The revised 2010 guidelines were implemented in May 2010.
Patients were seen at regular intervals for clinical and laboratory
monitoring and adherence assessment. All care was provided by
physicians. More information on the program has been published
before [15–17].
Validation Study of the Original CPS
Details of the original validation study have been previously
reported [10]. In brief, we conducted a cross-sectional study within
an established ART cohort in Cambodia between May 10, 2010
and June 3, 2011, including all consenting adults on a non-
nucleoside containing (standard) first-line regimen for a minimum
of one year (n = 1490). The original score – derived in this hospital
- contained eight items: 1) CD4 decline from peak .25%, 2) CD4
decline from peak .50%, 3) hemoglobin drop$1 g/dL over the
last six months, 4) current CD4 below baseline, 5) CD4 count ,
100 cells/mL at 12 month of ART, 6) papular pruritic eruption
(PPE), 7) treatment adherence ,95% (measured using a visual
analogue score); 8) ART-experience [8]. Summing the predictor
scores of the individual’s risk factors yielded the total predictor
score for each patient. Virological failure was defined as a VL
above 1000 copies/ml at the cross-sectional survey. The overall
test performance was assessed by calculating the area under the
receiver-operating characteristic curve (AUROC).
Development and Validation of Simplified CPS
The following simplified CPSs were evaluated with a progres-
sive increase in simplification by removing: 1) the ‘decline from
peak CD4 count values’ and only using ‘current’ CD4 count
(CPS1) - ie the value of the CD4 count at the time of assessment
for virological failure; 2) hemoglobin as item in the CPS (CPS2); 3)
‘decrease in CD4 count below baseline value’ as item in the CPS
(CPS3); and 4) all laboratory items from the CPS (CPS4).
The same methodology for score development was used as for
the original score derivation [8]. In brief, we used the Spiegelhalter
and Knill-Jones method adapted by Berkley et al [18–20].
Continuous variables were dichotomized as guided by ROC
curves. Variables independently associated with virological failure
with a likelihood ratio (LHR) $1.5 or #0.67 were retained. The
score of each predictor was calculated as the natural logarithm of
the adjusted LHR, rounded to the nearest integer. Summing the
predictor scores of the individual’s risk factors yielded the total
predictor score for each patient. For simplification, the score was
recoded by setting the reference level for each predictor to zero
[20]. The performance of the different CPSs was based on the
AUROC and 95% confidence intervals (CIs). A CPS was
considered clinically useful if, during validation, the lower limit
of the 95% CI was 0.6 or above. In addition, we calculated the
sensitivity, specificity, positive and negative predictive values, the
positive and negative likelihood ratio’s and proportion of
individuals that would require VL testing at the different cut-off
values of each CPS. The simplified scores were developed using
the same dataset of the study mentioned above, conducted in
2010–11. The different CPSs were validated in an independent
dataset from the same hospital (2005–2007), as reported before
[8]. In this study, patients were enrolled following the same
inclusion criteria as the 2010–2011 study mentioned above
(Table 1). Confidence intervals for the validated AUROCs were
calculated using robust standard errors.
Ethical Considerations
The VL validation study was approved by the National Ethics
Committee for Health Research, Phnom Penh, Cambodia; the
institutional review board (IRB) of the Institute of Tropical
Medicine, Antwerp, Belgium; and the Ethics Committee of the
University Hospital of Antwerp, Belgium. All study participants
provided written consent.
Results
A total of 1490 adults on first-line ART for at least one year
were included. As previously described, median time on ART at
the time of evaluation of virological treatment response was 3.6
(IQR 2.5–5.1) years. The median age at study inclusion was 38
(IQR 33–44) years and the median CD4 count was 379 (IQR
265–507) cells/mL. Approximately half (56.7%) were female and
.90% were on a zidovudine or stavudine-based regimen at the
time of evaluation. A total of 45 patients (3.0%) were detected with
virological failure.
In a first step (CPS1), we removed CD4 decline from peak
value, since it requires substantial calculation and complete on
treatment CD4 count data, but retained ‘current CD4 count’. The
AUROC of CPS1 was 0.78 (95% CI 0.70–0.85) in derivation and
0.69 (95% CI 0.62–0.75) in validation (Table 2). With the WHO
2013 guidelines arguing against routine hemoglobin monitoring -
even for patients using zidovudine - hemoglobin measurement was
additionally removed in CPS2. The validated AUROC decreased
to 0.68 (95% CI 0.62–0.74). To obtain a tool devoid of any
requirement of previous laboratory results (hence only relying on
‘‘current’’ lab tests), comparison with baseline CD4 count was
removed in CPS3. Only a slight decrease in AUROC was
observed. This provided a system essentially relying on basic
clinical information collected during routine patient assessment:
clinical evaluation (WHO T-stage, PPE, treatment information
(ART-experience and ART adherence) and CD4 response at the
time of assessment. No laboratory monitoring was included in
CPS4. However, this tool performed poorly (AUROC 0.59 in
Simple Clinical Scores for HIV Treatment Failure
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validation). The sensitivity, specificity, positive predictive value
and percentage of individuals requiring a VL at various score cut-
off values of the different CPS is given in Table 3, applying the
CPS in an independent dataset.
Discussion
We developed four simplified CPSs, of which three performed
relatively well and have a number of advantages. Compared to the
original CPS, no regular laboratory monitoring while on ART is
Table 1. Datasets used for the development and validation of the simplified prediction score to identify virological failure.
Derivation dataseta Validation dataseta,b
2010–2011 2005–2007
1490 individuals 1803 episodes
Age (years) at baseline, median (IQR) 35 (30–41) 34 (18–68)
Male sex, n (%) 646 (43.4) 925 (51.3)
Years on ART at viral load assessment, median (IQR) 3.6 (2.1–5.1) 1.5 (1.0–2.0)
Virological failure - n (%) 45 (3.0) 77 (4.8)
Initial ART regimen
D4T-3TC-NVP 1056 (70.9) 1369 (75.9)
D4T-3TC-EFV 343 (23.0) 261 (14.5)
AZT-3TC-NVP 62 (4.2) 106 (5.9)
AZT-3TC-EFV 24 (1.6) 63 (3.5)
Other 5 (0.4) 4 (0.2)
CD4 count, cells/mL, median (IQR)
Baseline (ART initiation) 94 (28–205) 54 (15–147)
At viral load assessment 379 (265–507) 281 (187–398)
aInclusion criteria: consecutive enrolment of adult patients ($18 years old) in follow-up at the Sihanouk Hospital Center of Hope on first-line ART for at least 12 months;
viral load was systematically performed for study purpose; virological failure was defined as a single measurement .1000 copies/ml;
bmore than one episodes per individual.
ART: antiretroviral treatment; AZT: zidovudine; D4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; IQR: interquartile range.
doi:10.1371/journal.pone.0087879.t001
Table 2. Content and diagnostic performance of the simplified clinical prediction scores to identify virological failurea.
CPS 1 CPS 2 CPS 3 CPS 4
No CD4 peak values No hemoglobin No CD4 baseline No lab investigations
AUROC derivation 0.78 0.75 0.75 0.63
(95% CI); (n =1490) (0.70–0.85) (0.68–0.83) (0.67–0.82) (0.56–0.70)
AUROC validation 0.69 0.68 0.67 0.59
(95% CI); (n =1803) (0.62–0.75) (0.62–0.74) (0.61–0.73) (0.53–0.65)
Items
CD4 decline from peak .25% Not included Not included Not included Not included
CD4 decline from peak .50% Not included Not included Not included Not included
Hemoglobin drop$1 g/dLb +1 Not included Not included Not included
Current CD4 below baseline +1 +1 Not included Not included
Current CD4,250 cells/mL +2 +2 +2 Not included
WHO T-stage Lb +1 +1 +1 +1
PPEb +2 +2 +2 +2
Adherence (VAS) ,95%c +1 +1 +2 +2
ART-experience +2 +1 +1 +1
ART: antiretroviral treatment; AUROC: area under the receiver-operating characteristic curve; CPS: clinical prediction score; PPE: papular pruritic eruption; VAS: visual
analogue scale.
adifferences between CPSs in the score of some predictors relate to the fact that the weight of each remaining predictor was recalculated after removing of specific
predictors (eg after removing hemoglobin in CPS2 vs CPS1).
bover a period of six months prior to viral load measurement.
cover a period of one month prior to viral load measurement.
doi:10.1371/journal.pone.0087879.t002
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required. Moreover, with a choice of CPS, programs can decide
which is most appropriate and feasible to apply in their program
settings. Performing hemoglobin measurement as part of an ART
monitoring strategy can be cumbersome in many settings, comes
with an additional cost and is not required in the latest WHO
guidelines. Moreover, the added value in terms of diagnostic
performance was limited, especially at lower cut-off values. CPS2
and CPS3 seem most useful and practical. CPS2 could be used
when a baseline CD4 cell count is available, while CPS3 would
apply when patients have initiated ART without CD4 guidance.
With only a limited amount of key clinical information and
minimal calculation required, these CPSs are also substantially
simpler and possibly more adapted for use by non-physicians.
Some resource-constrained countries predominantly use clinical
monitoring to detect treatment failure and CD4 cell counts are not
always regularly done while on ART, especially in remote areas.
However, we found that, in line with previous studies, CPS4 -
relying on clinical information only - performed poorly [2].
Adding a CD4 cell count test ‘on the spot’ would substantially
improve the performance of the algorithm without requiring
routine CD4 monitoring. Current CD4 count was also found to be
a strong predictor in a Ugandan scoring system [9]. Of interest,
the same CD4 count cut-off (250 cells/mL) was identified in a
recent study using data from the DART trial [21]. Pending the
development of an affordable and widely available point of care
VL test, use of these CPSs combined with targeted VL testing
should be considered. If CD4 count testing can be done ‘on site’ or
with a point of care test [22], application of the CPS could be done
within one day. If not, patients might need two visits to apply the
CPS. However, this creates an additional burden for both patients
and health care staff, and increases chances for delays and missed
appointments.
Further study is required to determine at what time points
during ART these scores should be applied, and in which different
health care settings and patient populations. Moreover, these
algorithms were designed for patients on ART for at least one
year. One approach could consist of a routine VL early after ART
initiation (eg six months after ART initiation) followed by
application of the score at predefined intervals, combined with
targeted VL testing. Whereas applying the score every six months
would equate to routine CD4 count monitoring, the current CPS
would still have the advantage of not requiring interpretation of a
trend of laboratory tests. While these simplifications would likely
render them easier to apply and less error-prone compared to the
original CPS, this is subject to further study.
A number of issues remain to be assessed before implementing
these CPSs in routine care. Validation in other study populations
and different settings should be conducted. Additional studies on
the clinical utility and impact are warranted [23,24]. The study
population in this analysis consisted of patients on ART for several
years. Possibly, the optimal ‘current CD4 cell count’ cut-off might
differ in patient populations with short or very long treatment
duration. Moreover, most patients in our cohort started ART with
relatively advanced HIV disease. It remains to be assessed whether
the performance of the CPSs would be different in patients starting
early ART, as would occur within a test-and-treat strategy.
Additional limitations include the fact that treatment failure was
based on a single VL measurement, in line with the previous
derivation and validation study. Since a substantial proportion
might have an undetectable VL on repeat measurement, only a
proportion of those with virological failure in our study would be
true treatment failures. On the other hand, the main purpose of
targeted VL testing is early detection of active viral replication,
since these patients need enhanced adherence counseling followed
by a repeat VL. We did not evaluate whether individual
opportunistic infections should be included as predictors in the
CPS, but used ‘pooled’ WHO clinical staging groups. While this
might be a more ‘crude’ approach, it has the advantage of being
simpler. Finally, the failure rate in our study was clearly lower than
what has been observed in most other programs. Consequently,
positive predictive values will be higher and negative predictive
values lower in settings with higher failure rates.
We acknowledge that the present algorithms are unlikely to be
universally applicable and generalizable across a wide range of
geographical regions, populations and health care settings.
Derivation and validation of algorithms for local use (eg at the
country or regional level) might be a reasonable alternative, and
might also be valuable for a wider range of diagnostic tests or
health care interventions. Targeted evaluation using evidence-
based tools might be a rational way to optimize the use of often
scarce resources available for health delivery in LMIC [2]. At the
same time, such an approach also appreciates that patient
populations are not homogeneous, but consist of different ‘risk
groups’ with different needs and benefits of testing and other
interventions. Especially as long as cheap point of care tests are
lacking, such approaches merit further study.
In conclusion, we have developed three simplified CPSs for
targeted VL testing that retained an acceptable diagnostic
performance as long as ‘spot’ CD4 testing was included. They
have the advantages of not requiring regular CD4 cell count or
hemoglobin testing, or complete and reliable data collection while
on ART, or the need to interpret trends in laboratory tests. They
Table 3. Diagnostic performance at different cut-offs of the
clinical prediction scores to identify virological failure using an
independent dataset.
Score Sensitivity Specificity PPV
% VL
done LHR(+) LHR(2)
CPS 1
$1 80.5 36.5 6.0 64.3 1.27 0.54
$2 73.6 50.3 7.0 50.8 1.48 0.52
$3 49.4 80.4 11.3 21.1 2.52 0.63
$4 34.5 92.1 18.1 9.2 4.35 0.71
CPS 2
$1 79.1 41.0 6.4 60.0 1.34 0.50
$2 72.4 54.8 7.5 46.5 1.60 0.50
$3 41.4 84.7 12.1 16.5 2.71 0.69
$4 24.1 95.9 23.1 5.0 5.92 0.79
CPS 3
$1 78.2 41.3 6.3 60.0 1.33 0.53
$2 72.4 54.8 7.5 46.5 1.6 0.50
$3 36.8 85.7 11.6 15.4 2.58 0.74
$4 21.8 96.3 22.9 4.6 5.86 0.81
CPS 4
$1 43.7 70.0 6.9 30.6 1.46 0.80
$2 25.3 91.5 13.2 9.3 2.99 0.82
$3 9.2 97.8 17.8 2.5 4.26 0.93
$4 1.1 99.9 33.3 0.2 9.86 0.99
CPS: clinical prediction score; PPV: positive predictive value; % VL done:
percentage of patients that would undergo targeted VL testing; LHR: likelihood
ratio.
doi:10.1371/journal.pone.0087879.t003
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should, therefore, be less prone to error and more readily adopted
in field conditions. Their use would enable more accurate targeted
VL testing in contexts where it is too expensive to be done
routinely. We suggest that they be tested and tailored to the other
health care settings.
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